Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
SMMT
SMMT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SMMT News
Growth Prospects for the EGFR-NSCLC Market Analyzed
3d ago
Newsfilter
Exelixis and Summit Therapeutics: Promising Drug Candidates Ahead
Feb 01 2026
NASDAQ.COM
Exelixis and Summit Therapeutics: Future Prospects
Feb 01 2026
Fool
Summit Therapeutics Grants Stock Options to New Employees
Jan 30 2026
Newsfilter
FDA Accepts Summit Therapeutics' BLA for Ivonescimab
Jan 29 2026
Benzinga
Summit Therapeutics' FDA Application Accepted for Ivonescimab
Jan 29 2026
seekingalpha
Summit Submits BLA for Ivonescimab in NSCLC
Jan 29 2026
Newsfilter
Akeso's Ivonescimab Selected as Key Drug for 2026
Jan 29 2026
Yahoo Finance
Regencell Bioscience Holdings (RGC) Shares Plunge 42.08% Amid Market Decline
Jan 18 2026
Benzinga
Biotech Insider Buying Signals Strong, Three Companies Draw Attention
Jan 15 2026
Benzinga
U.S. Markets Rose on Monday, with MACOM Tech Solutions Leading the Gains
Jan 12 2026
Barron's
CRISPR Therapeutics and Summit Therapeutics: Investment Outlook for 2026
Jan 12 2026
Fool
Gold and Silver Hit Record Highs as Investors Reassess Fed Independence Amid Political Tensions
Jan 12 2026
Benzinga
Summit Therapeutics Grants Inducement Awards for 214,331 Shares to New Employees
Jan 10 2026
Businesswire
Alumis Surges 95.31% on Phase 3 Psoriasis Data, Plans $175M Offering
Jan 06 2026
Fool
Alumis (ALMS) Shares Surge 95% Following Phase 3 Psoriasis Data and $175M Offering Plan
Jan 06 2026
NASDAQ.COM
Show More News
